Browse > Article
http://dx.doi.org/10.7314/APJCP.2013.14.7.4369

Clinical Observations on the Association Between Diagnosis of Lung Cancer and Serum Tumor Markers in Combination  

Wang, Wen-Jing (Department of Infectious Diseases, Nanjing First Hospital, Nanjing Medical University)
Tao, Zhen (Department of Infectious Diseases, Nanjing First Hospital, Nanjing Medical University)
Gu, Wei (Department of Respiration, Nanjing First Hospital, Nanjing Medical University)
Sun, Li-Hua (Department of Respiration, Nanjing First Hospital, Nanjing Medical University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.14, no.7, 2013 , pp. 4369-4371 More about this Journal
Abstract
Objective: To evaluate the association of a diagnosis of lung cancer and combined detection of serum carcinoembryonic antigen (CEA), carbohydrateantigen 19-9 (CA19-9), neuron specific enolase (NSE) as well as the cytokeratin 19 fragment (CYFRA21-1). Methods: Serum CEA, CA19-9, NSE and CYFRA21-1 were assessed in 150 patients with lung cancer, 100 patients with benign lung disease and 100 normal control subjects, and differences of expression were compared in each group, and joint effects of these tumor markers in the diagnosis of lung cancer were analyzed. Results: Serum CEA, CA19-9, NSE and CYFRA21-1 in patients with lung cancer were significantly higher than those with benign lung disease and normal controls (p<0.01). It is suggested that these four tumor markers combined together could produce a positive detection rate of 90.2%, significantly higher than that of any single test. Conclusion: Combination detection of CEA, CA19-9, NSE and CYFRA21-1 could significantly improve the sensitivity and specificity in diagnosis of lung cancer, and could be important in early detection.
Keywords
Lung cancer; CEA; CA199; NSE; CYFRA21-1;
Citations & Related Records
Times Cited By KSCI : 9  (Citation Analysis)
연도 인용수 순위
1 Ardizzoni A, Cafferate MA, Tiseo M, et al (2006). Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer. Cancer, 107, 2842-9.   DOI   ScienceOn
2 Bilgin E, Dizdar Y, Serilmez M, et al (2013). For which cancer types can neuron-specific enolase be clinically helpful in Turkish patients? Asian Pac J Cancer Prev, 14, 2541-4.   DOI   ScienceOn
3 Buccheri G, Eerrigno D (2002). Lung tumor markers in oncology practice: a study of TPA and CA125. Br J Cancer, 87, 1112-8.   DOI   ScienceOn
4 Cho JY, Sung HJ (2009). Proteomic approaches in lung cancer biomarker development. Expert Rev Proteomics, 6, 27-42.   DOI   ScienceOn
5 Fletcher CD, Berman JJ, Corless C, et al (2002). Diagnosis of gastrointestinal stromal tumoes: a consensus approach. Hum Patnol, 33, 459-65.   DOI   ScienceOn
6 Hu LA, Fu Y, Zhang DN, et al (2013). Serum IL-33 as a diagnostic and prognostic marker in non- small cell lung cancer. Asian Pac J Cancer Prev, 14, 2563-6.   DOI   ScienceOn
7 Kav S, Tokdemir G, Tasdemir R, et al (2012). Patients with cancer and their relatives beliefs, information needs and information-seeking behavior about cancer and treatment. Asian Pac J Cancer Prev, 13, 6027-32.   DOI   ScienceOn
8 Liu YC, Zhou SB, Gao F, et al (2013). Chemotherapy and late course three dimensional conformal radiotherapy for treatment of patients with Stage III non-small cell lung cancer. Asian Pac J Cancer Prev, 14, 2663-5.   DOI   ScienceOn
9 Lu YY, Huang XE, Xu L, et al (2013). Potential predictors of sensitivity to pemetrexed as first-line chemotherapy for patients with advanced non-squamous NSCLCs. Asian Pac J Cancer Prev, 14, 2005-8.   DOI   ScienceOn
10 Malik PS, Sharma MC, Mohanti BK, et al (2013). Clinicopathological profile of lung cancer at AIIMS: a changing paradigm in India. Asian Pac J Cancer Prev, 14, 489-94.   DOI   ScienceOn
11 Oguz A, Unal D, Tasdemir A, et al (2013). Lack of any association between blood groups and lung cancer, independent of histology. Asian Pac J Cancer Prev, 14, 453-6.   DOI   ScienceOn
12 Pan JB, Hou YH, Zhang GJ (2013). Correlation between EGFR mutations and serum tumor markers in lung adenocarcinoma patients. Asian Pac J Cancer Prev, 14, 695-700.   DOI   ScienceOn
13 Parkin DM, Brary FB, Pisani P (2005). Global cancer statistics. Cancer J Clin, 55, 74-108.   DOI   ScienceOn
14 Ramshankar V, Krishnamurthy A (2013). Lung cancer detection by screening - presenting circulating miRNAs as a promising next generation biomarker breakthrough. Asian Pac J Cancer Prev, 14, 2167-72.   DOI   ScienceOn
15 Schneider J, Bitterlich N, Velcovsky HG, et al (2002). Fuzzy logic based tumor marker profiles improved sensitivity in the diagnosis of lung cancer. Int J Clin Oncol, 7, 145-51.   DOI